http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3674421-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a3a94888eda15bcc34c9c5c235230463 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-118 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-172 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q2600-158 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6886 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-6886 |
| filingDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_514b4be8143840644b106a1641d95d8c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_82bdbf433ab0f0fb075bae77cfe392f4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_24eace60f3932525c6fbab8c293629f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f1afd774f5833f4cffc151b3eb280b6c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_302ac268c147dec7014ddefdb0e0db38 |
| publicationDate | 2020-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | EP-3674421-A1 |
| titleOfInvention | Methods for the prognosis of prostate cancer |
| abstract | The present invention relates to methods useful for predicting the outcome of a patient suffering from prostate cancer or for predicting the response to therapy of a patient suffering from prostate cancer, which comprise determining, in a sample from the patient, the ratio between the average expression levels of a first gene signature and the average expression levels of a second gene signature, wherein the first gene signature is selected from the group consisting of HI1 (i.e., the CPOX, GAL3St4, ORAI2 and NIPA1 genes) and HI2 (i.e., the KHK, NOX4, PTGES3 and RRM2 genes); wherein the second gene signature is selected from the group consisting of LO1 (i.e., the ATP8B1, CDO1, CHRNA2, GLB1L3, GNE, KATNAL2, PTGIS, SLC6A14, TP53INP2, and TRIM47 genes), LO2 (i.e., the ASPA, CDO1, CYP3A5, GLB1L2, GNE, ITPKC, KCTD14, PAH, PHYHD1, SIRT1, SLC40A1, SLC7A4, and SRD5A genes) and LO3 (i.e., the ASPA, CDO1, GFPT2, GNE, ITPKC, PAH, SIRT1 and TPMT genes). These methods can be used to identify those patients who harbour an indolent/ low risk prostate cancer, or those that are at a high risk of recurrence or metastasis. The identification of these subgroups of patients may guide the selection of therapies, improving financial and health outcomes. Moreover, the expression levels of these genes can also be used for the selection of a patient to be treated for low risk, indolent, localised, advanced, recurrent or metastatic prostate cancer. Further, the invention also relates to kits and reagents to determine the expression levels of these genes. |
| priorityDate | 2018-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 683.